PDS Planning Inc Raises Stock Position in Pfizer Inc. (NYSE:PFE)

PDS Planning Inc grew its position in Pfizer Inc. (NYSE:PFE) by 4.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,147 shares of the biopharmaceutical company’s stock after buying an additional 1,439 shares during the period. PDS Planning Inc’s holdings in Pfizer were worth $865,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Vanguard Group Inc. boosted its position in shares of Pfizer by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock worth $13,756,738,000 after purchasing an additional 2,285,276 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after purchasing an additional 2,923,537 shares during the period. Norges Bank acquired a new stake in Pfizer during the 4th quarter worth $2,328,986,000. Finally, Massachusetts Financial Services Co. MA increased its position in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.1%

PFE stock opened at $24.29 on Thursday. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The firm has a 50 day simple moving average of $23.38 and a 200-day simple moving average of $24.87. The company has a market capitalization of $138.10 billion, a P/E ratio of 17.60, a PEG ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.82 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.08%. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.